{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:43:22Z","timestamp":1781606602210,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ymgme.2024.109000","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T05:40:02Z","timestamp":1734327602000},"page":"109000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Use of a mouse\u2013human chimeric anti-\u03b1-galactosidase A monoclonal antibody as a reference for measuring serum antidrug antibody titers in patients with Fabry disease"],"prefix":"10.1016","volume":"144","author":[{"given":"Takahiro","family":"Tsukimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadayasu","family":"Togawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Gojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Sakuraba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2024.109000_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2024.109000_bb0010","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/jmedgenet-2019-106467","article-title":"Use of a rare disease registry for establishing phenotypic classification of previously unassigned GLA variants: a consensus classification system by a multispecialty Fabry disease genotype-phenotype workgroup","volume":"57","author":"Germain","year":"2020","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2024.109000_bb0015","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of alpha-galactosidase a reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2024.109000_bb0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"International collaborative Fabry disease study group, safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2024.109000_bb0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ymgme.2020.04.003","article-title":"Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: phase I and II\/III clinical studies","volume":"130","author":"Nakamura","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.109000_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2024.1395287","article-title":"Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease","volume":"15","author":"Germain","year":"2024","journal-title":"Front. Genet."},{"key":"10.1016\/j.ymgme.2024.109000_bb0035","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/GIM.0b013e3181f13b75","article-title":"Effects of enzyme replacement therapy in Fabry disease-a comprehensive review of the medical literature","volume":"12","author":"Lidove","year":"2010","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2024.109000_bb0040","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.2147\/DDDT.S207856","article-title":"FOS study group, cardio-renalcardio-renal outcomes with long-term agalsidase alfa enzyme replacement therapy: a 10-year Fabry outcome survey (FOS) analysis","volume":"13","author":"Ramaswami","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymgme.2024.109000_bb0045","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/ckj\/sfaa065","article-title":"Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis","volume":"14","author":"Ortiz","year":"2021","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.ymgme.2024.109000_bb0050","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ymgme.2018.11.008","article-title":"Antibodies against recombinant alpha-galactosidase a in Fabry disease: subclass analysis and impact on response to treatment","volume":"126","author":"van der Veen","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.109000_bb0055","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13023-018-0877-4","article-title":"Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY","volume":"13","author":"Mauhin","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2024.109000_bb0060","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1365-2125.2009.03501.x","article-title":"Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies","volume":"68","author":"Tesmoingt","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ymgme.2024.109000_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase a in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymgme.2024.109000_bb0070","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10545-011-9400-y","article-title":"Fabry disease, enzyme replacement therapy and the significance of antibody responses","volume":"35","author":"Deegan","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2024.109000_bb0075","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2024.109000_bb0080","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1681\/ASN.2014121226","article-title":"Serum-mediated inhibition of enzyme replacement therapy in Fabry disease","volume":"27","author":"Lenders","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2024.109000_bb0085","article-title":"Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy","volume":"25","author":"Tsukimura","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2024.109000_bb0090","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s13730-022-00738-7","article-title":"Monitoring of anti-drug antibodies and disease-specific biomarkers in three patients from a Japanese Fabry family treated with enzyme replacement therapy","volume":"12","author":"Kubota","year":"2023","journal-title":"CEN Case Rep."},{"key":"10.1016\/j.ymgme.2024.109000_bb0095","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s13730-023-00843-1","article-title":"Effects of switching from agalsidase-alpha to agalsidase-beta on biomarkers, renal and cardiac parameters, and disease severity in Fabry disease forming neutralizing antidrug antibodies: a case report","volume":"13","author":"Shima","year":"2024","journal-title":"CEN Case Rep."},{"key":"10.1016\/j.ymgme.2024.109000_bb0100","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2165\/11318300-000000000-00000","article-title":"Enzyme replacement therapy for Fabry disease: a systematic review of available evidence","volume":"69","author":"Schaefer","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.ymgme.2024.109000_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128351","article-title":"Rapid immunochromatographic detection of serum anti-\u03b1-galactosidase a antibodies in Fabry patients after enzyme replacement therapy","volume":"10","author":"Nakano","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymgme.2024.109000_bb0110","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.3390\/ijms22052680","article-title":"Generation and characterization of a polyclonal human reference antibody to measure anti-drug antibody titers in patients with Fabry disease","volume":"22","author":"Lenders","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2024.109000_bb0115","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1128\/CVI.00114-07","article-title":"Use of chimeric antibodies as positive controls in an enzyme-linked immunosorbent assay for diagnosis of scrub typhus (infection by Orientia tsutsugamushi)","volume":"14","author":"Jones","year":"2007","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.ymgme.2024.109000_bb0120","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1128\/CVI.00354-08","article-title":"Development of a human-murine chimeric immunoglobulin M antibody for use in the serological detection of human Flavivirus antibodies","volume":"16","author":"Thibodeaux","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.ymgme.2024.109000_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.intimp.2007.09.020","article-title":"Engineering and characterization of a mouse\/human chimeric anti-phencyclidine monoclonal antibody","volume":"8","author":"Lacy","year":"2008","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ymgme.2024.109000_bb0130","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1128\/JCM.36.5.1277-1284.1998","article-title":"Recombinant mouse-human chimeric antibodies as calibrators in immunoassays that measure antibodies to toxoplasma gondii","volume":"36","author":"Hackett","year":"1998","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ymgme.2024.109000_bb0135","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/cmdc.201800094","article-title":"Antibody epitope of human \u03b1-galactosidase a revealed by affinity mass spectrometry: a basis for reversing immunoreactivity in enzyme replacement therapy of Fabry disease","volume":"13","author":"Kukacka","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ymgme.2024.109000_bb0140","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ymgme.2020.08.005","article-title":"Detailed epitope mapping of neutralizing anti-drug antibodies against recombinant \u03b1-galactosidase a in patients with Fabry disease","volume":"131","author":"Scharnetzki","year":"2020","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224008849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224008849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T22:44:03Z","timestamp":1738449843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719224008849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1096719224008849"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.109000","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of a mouse\u2013human chimeric anti-\u03b1-galactosidase A monoclonal antibody as a reference for measuring serum antidrug antibody titers in patients with Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.109000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109000"}}